Microbot Medical (NASDAQ: MBOT) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.
This is a breakdown of current ratings for Microbot Medical and Mesoblast, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Microbot Medical and Mesoblast’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
5.1% of Microbot Medical shares are held by institutional investors. Comparatively, 2.9% of Mesoblast shares are held by institutional investors. 31.8% of Microbot Medical shares are held by company insiders. Comparatively, 18.8% of Mesoblast shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
Microbot Medical has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500. Comparatively, Mesoblast has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500.
Earnings & Valuation
This table compares Microbot Medical and Mesoblast’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Microbot Medical||$120,000.00||234.61||-$9.66 million||N/A||N/A|
|Mesoblast||$2.41 million||221.55||-$76.81 million||($0.97)||-5.85|
Microbot Medical has higher earnings, but lower revenue than Mesoblast.
About Microbot Medical
Microbot Medical Inc., formerly StemCells, Inc., is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures. Its ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. The Microbot SCS device is a robotic system designed as the ventricular catheter portion of a cerebrospinal fluid (CSF) shunt system. The Company’s TipCAT is an endoscope that provides see and treat capabilities within tubular lumens in the human body, such as the colon, blood vessels and the urinary tract.
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.